Baroda BNP Paribas Health and Wellness Fund
Direct · GrowthAI Summary
The fund delivered a 1Y SIP XIRR of 20.94%, well above the category average SIP XIRR of 10.7% for the same period. Against the NIFTY 50, it generated strong alpha of 8.18% over 1Y with a Fund CAGR of 6.72% versus the benchmark's -9.19%. However, longer-term lump-sum CAGRs remain modest, with 3Y at 1.26% and 5Y at 0.75%, though these still exceeded the benchmark's negative returns.
The fund exhibits low volatility relative to the market, with a beta of roughly 0.51-0.53 and downside capture of only 41.77% over 1Y, meaning it fell less than half as much as the NIFTY 50 during declines. Maximum drawdown was minimal at -0.11% with a 183-day duration and 110-day recovery, and only one drawdown event exceeded 10%. The 1Y Calmar ratio of 0.8885 reflects reasonable risk-adjusted returns given the shallow drawdown profile.
The portfolio is heavily concentrated in Pharmaceuticals & Biotechnology at 73.7% of NAV, with Healthcare Services adding 19.8%, making it a near-pure healthcare play. Top holdings include Sun Pharmaceutical (8.58%), Torrent Pharmaceuticals (7.88%), and Divi's Laboratories (7.82%), with the top 10 holdings comprising roughly 58% of the 33-stock portfolio. This concentration offers focused exposure but leaves little diversification beyond the healthcare theme.
The fund's 1Y SIP XIRR of 20.94% significantly outpaces the category average of 10.7%, indicating strong recent relative performance. However, the negative alpha trend over longer horizons (-0.0006% at 3Y declining to -2.43% at 15Y) suggests the fund has lagged its own risk-adjusted expectations over extended periods. Calendar year returns show mixed consistency, with 9.07% in 2026 but -4.62% in 2025.
This fund suits investors seeking targeted exposure to India's healthcare and pharmaceutical sector as a satellite holding within a broader diversified portfolio. Given the sector concentration and modest long-term lump-sum returns, a horizon of at least 5-7 years is advisable to ride through sector cycles. Investors should have moderate-to-high risk tolerance, as thematic funds can underperform significantly during unfavorable sector phases despite the fund's low beta.
- 1Y SIP XIRR of 20.94% more than doubles the category average of 10.7%
- Low beta of 0.51-0.53 and downside capture of 41.77% provide strong downside protection versus the NIFTY 50
- Minimal maximum drawdown of -0.11% with a 110-day recovery indicates resilient drawdown behavior
- Extreme sector concentration with 93.5% in just two sectors (Pharma 73.7%, Healthcare Services 19.8%) exposes investors to single-theme risk
- Negative alpha across all horizons beyond 1Y (e.g., -1.21% at 5Y and -2.43% at 15Y) suggests persistent long-term underperformance versus risk expectations
Generated on 20-10-2026, 3:10 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹13.18 L | 19.7% | 6.4% | 29.1% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 19.7% | 14.3% | 10.7% | +5.5% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 9.7% | 10.4% | 4.0% | 15.0% | 1.11 | 6.37 | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +6.38 | 0.51 | 55.0% | 42.2% | 3.8% | -11.4% |
| 3 Years | -0.34 | 0.53 | 57.3% | 48.2% | 0.8% | -3.5% |
| 5 Years | -1.41 | 0.53 | 57.3% | 48.2% | 0.5% | -2.1% |
| 7 Years | -1.88 | 0.53 | 57.3% | 48.2% | 0.4% | -1.5% |
| 10 Years | -2.23 | 0.53 | 57.3% | 48.2% | 0.3% | -1.1% |
| 12 Years | -2.36 | 0.53 | 57.3% | 48.2% | 0.2% | -0.9% |
| 15 Years | -2.49 | 0.53 | 57.3% | 48.2% | 0.2% | -0.7% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited | 8.58% |
| 2 | Torrent Pharmaceuticals Limited | 7.88% |
| 3 | Divi's Laboratories Limited | 7.82% |
| 4 | IPCA Laboratories Limited | 6.13% |
| 5 | Laurus Labs Limited | 6.09% |
| 6 | Lupin Limited | 5.79% |
| 7 | Apollo Hospitals Enterprise Limited | 5.28% |
| 8 | Fortis Healthcare Limited | 3.98% |
| 9 | Dr. Lal Path Labs Limited | 3.47% |
| 10 | Mankind Pharma Limited | 3.34% |